| Patents for A61P 7 - Drugs for disorders of the blood or the extracellular fluid (67,065) |
|---|
| 03/21/2002 | WO2001081346A3 Inhibitors of human phosphatidyl-inositol 3-kinase delta |
| 03/21/2002 | WO2001078529A3 Compositions and methods for improving vascular health |
| 03/21/2002 | WO2001077376A8 Diagnosis of diseases associated with metastasis |
| 03/21/2002 | WO2001077164A8 Diagnosis of diseases associated with apoptosis by means of assessing the methylation status of genes associated with apoptosis |
| 03/21/2002 | WO2001074902A3 Adenine binding g protein coupled receptors |
| 03/21/2002 | WO2001070694A8 Amorphous torasemide modification |
| 03/21/2002 | WO2001068568A3 Il-8 receptor antagonists |
| 03/21/2002 | WO2001064165A3 Il-8 receptor antagonists |
| 03/21/2002 | WO2001062905A3 Integrin antagonists |
| 03/21/2002 | WO2001055106A3 Novel melanocortin receptor agonists and antagonists |
| 03/21/2002 | WO2001051638A3 Drug metabolizing enzymes |
| 03/21/2002 | WO2001051510A3 G-csf conjugates |
| 03/21/2002 | WO2001041754A3 Inhibitors of collagen-induced platelet aggregation |
| 03/21/2002 | WO2001035943A3 Dextrose and insulin fluid formulation for intravenous infusion |
| 03/21/2002 | WO2001034136A3 Use of adatanserin for the treatment of neurodegenerative conditions |
| 03/21/2002 | US20020035394 Methods and apparatus for stenting comprising enhanced embolic protection, coupled with improved protection against restenosis and thrombus formation |
| 03/21/2002 | US20020035140 1-(pyrrlolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
| 03/21/2002 | US20020035135 Oral administering; storage stability |
| 03/21/2002 | US20020035127 Phenylalanine derivatives |
| 03/21/2002 | US20020035118 Low molecular weight cell, bone marrow and immune stimulants |
| 03/21/2002 | US20020035110 Treatment or prevention of disorders of the central nervous system, cardiovascular disorders, gastrointestinal disorders, diabetes insipidus, and sleep apnea |
| 03/21/2002 | US20020035109 Benzamidine derivatives and their use as anti-coagulants |
| 03/21/2002 | US20020035092 Propanoic acid derivatives |
| 03/21/2002 | US20020034787 Nucleotide sequences coding polypeptides for use in treatment of wounds, burns, ulcers, nervous system disorders and tumors |
| 03/21/2002 | DE10045047A1 Arzneimittel enthaltend aktiviertes Antithrombin III Medicines containing activated antithrombin III |
| 03/21/2002 | DE10044325A1 Neue MMP-2-Derivate als Inhibitoren des Integrins avbeta3 New MMP-2 derivatives as inhibitors of the integrin avbeta3 |
| 03/21/2002 | CA2432780A1 Interheteroaryl 7-oxabicyclic [2.2.1]heptane oxazoles as prostaglandin f25g(a) antagonists |
| 03/21/2002 | CA2422376A1 Isoxazoles and their use as inhibitors of erk |
| 03/21/2002 | CA2422233A1 Interphenylene 7-oxabicyclic[2.2.1]heptane oxazoles as prostaglandin f2aantagonists |
| 03/21/2002 | CA2422137A1 Tetrahydroquinoline compounds |
| 03/21/2002 | CA2422095A1 Tweak receptor agonists as anti-angiogenic agents |
| 03/21/2002 | CA2422076A1 Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination |
| 03/21/2002 | CA2422032A1 The diagnosis, prevention, amelioration and/or treatment of disturbed immune function induced by disturbed lipid metabolism |
| 03/21/2002 | CA2421994A1 The diagnosis, prevention, and/or treatment of atherosclerosis and underlying and/or related diseases |
| 03/21/2002 | CA2421792A1 Alpha v integrin receptor antagonists |
| 03/21/2002 | CA2421786A1 Compounds and methods for inhibiting alpha-1 beta-1 integrins |
| 03/21/2002 | CA2421279A1 2-amino-2-alkyl-3 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 03/21/2002 | CA2420450A1 2-amino-2-alkyl-3 hexenoic and hexynoic acid derivatives useful as nitric oxide synthase inhibitors |
| 03/21/2002 | CA2418720A1 Caspase inhibitors and uses thereof |
| 03/20/2002 | EP1188773A1 Nitroderivatives of polysaccharides |
| 03/20/2002 | EP1188442A2 Cinnamomi and poria composition, method to prepare the same and uses thereof |
| 03/20/2002 | EP1188440A1 Medicinal composition for oral administration |
| 03/20/2002 | EP1188438A1 Pharmaceutical composition for preventing or treating a disease associated with an excess of Il-12 production |
| 03/20/2002 | EP1187931A1 49 human secreted proteins |
| 03/20/2002 | EP1187916A2 Identification and molecular characterisation of proteins, expressed in the tick salivary glands |
| 03/20/2002 | EP1187843A1 Angiogenic proteins and uses thereof |
| 03/20/2002 | EP1187836A1 Substituted imidazothiazoles as antidepressant agents |
| 03/20/2002 | EP1187825A1 Thiophene integrin inhibitors |
| 03/20/2002 | EP1187616A1 Thrombin inhibitors |
| 03/20/2002 | EP1187613A1 Amide substituted imidazoquinolines |
| 03/20/2002 | EP1187531A1 Macrophage scavenger receptor antagonists |
| 03/20/2002 | EP0944590B1 Aminoguanidines and alkoxyguanidines as protease inhibitors |
| 03/20/2002 | EP0591385B1 Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
| 03/20/2002 | EP0418316B1 Platelet-specific chimeric immunoglobulin |
| 03/20/2002 | CN1341099A 2-aminopyridines containing fused ring substituents |
| 03/20/2002 | CN1341028A New use of melagatran |
| 03/20/2002 | CN1341027A Inhibitors for use in hemostasis and immune function |
| 03/19/2002 | US6359182 C-nitroso compounds and use thereof |
| 03/19/2002 | US6359158 A 16-hydroxyeicosatetraenoic acid antagonist; antiinflammatory agents |
| 03/19/2002 | US6359136 Antithrombotic agents |
| 03/19/2002 | US6359134 Sulfonamide derivatives, their production and use |
| 03/19/2002 | US6359014 Polyoxypropylene/polyoxyethylene copolymers with improved biological activity |
| 03/19/2002 | US6358989 Therapeutic inhibitor of vascular smooth muscle cells |
| 03/19/2002 | US6358976 For therapy and prophylaxis of cancer metastasis, diabetic retinopathy, neovascular glaucoma, thrombosis, restenosis, osteoporosis, or macular degeneration |
| 03/19/2002 | US6358954 PDGF receptor kinase inhibitory compounds, their preparation, purification and pharmaceutical compositions including same |
| 03/19/2002 | US6358945 Compounds useful as anti-inflammatory agents |
| 03/19/2002 | US6358923 Preventing and diagnosing blood, genetic, and nervous system disorders associated with decreased genetic expression |
| 03/19/2002 | US6358732 Nucleotide sequences preferential polypeptides for use in the treatment of defects in central nervous system |
| 03/19/2002 | US6358703 Expression system for factor VIII |
| 03/19/2002 | US6358534 For therapy of hemophilia |
| 03/19/2002 | CA2319966A1 Improved dextran-hemoglobin conjugate as potential blood substitute |
| 03/19/2002 | CA2131316C A thrombin blood fraction for use in a medical procedure |
| 03/19/2002 | CA2032797C Antithrombotic compounds |
| 03/19/2002 | CA2008390C Mutants of human antithrombin iii |
| 03/19/2002 | CA2007075C New thrombolytic compositions |
| 03/15/2002 | CA2357155A1 Pharmaceutical composition for preventing or treating a disease associated with an excess of il-12 production |
| 03/14/2002 | WO2002020822A2 Biopanning and rapid analysis of selective interactive ligands (brasil) |
| 03/14/2002 | WO2002020802A1 A cell line expressing mutant human tissue-type plasminogen activator, constructing strategy and method of expressed protein preparation |
| 03/14/2002 | WO2002020767A2 G-csf analog compositions and methods |
| 03/14/2002 | WO2002020766A2 G-csf analog compositions and methods |
| 03/14/2002 | WO2002020736A2 Proteases |
| 03/14/2002 | WO2002020724A2 Adenoviral targeting and manipulation of immune system response using targeting peptides |
| 03/14/2002 | WO2002020723A2 Compositions and methods for targeting peptides in humans in vivo |
| 03/14/2002 | WO2002020722A2 Methods and compositions for in vitro targeting |
| 03/14/2002 | WO2002020513A1 Oxindole derivatives |
| 03/14/2002 | WO2002020489A2 QUINOLINE INHIBITORS OF cGMP PHOSPHODIESTERASE |
| 03/14/2002 | WO2002020091A2 Antithrombotic compositions |
| 03/14/2002 | WO2002020049A2 Eiav chimeric vaccine and diagnostic |
| 03/14/2002 | WO2002020034A1 'pseudo'-native chemical ligation |
| 03/14/2002 | WO2002020033A1 Polymer-modified synthetic proteins |
| 03/14/2002 | WO2002019963A2 Synthetic erythropoiesis stimulating proteins |
| 03/14/2002 | WO2001085760A8 Thrombin inhibitors |
| 03/14/2002 | WO2001070734A3 Beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha |
| 03/14/2002 | WO2001070673A3 CYCLIC β-AMINO ACID DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEASES AND TNF-$g(a) |
| 03/14/2002 | WO2001066081A3 Pharmaceutical preparations containing saccharose fatty acid esters for controlling the release of active ingredients |
| 03/14/2002 | WO2001055130A3 Novel 1,3-dihydro-2h-indol-2-one derivatives and their use as ligands for v1b and v1a arginine-vasopressin receptors |
| 03/14/2002 | WO2001049264A3 Pharmaceutical compositions for oral administration |
| 03/14/2002 | WO2001032130A3 Phenyl amine carboxylic acid compounds and compositions for delivering active agents |
| 03/14/2002 | WO2000065028A9 TGF-α POLYPEPTIDES, FUNCTIONAL FRAGMENTS AND METHODS OF USE THEREFOR |
| 03/14/2002 | WO2000058483A9 Protozoan expression system |